Zusammenfassung
Chronischer Pruritus tritt bei zahlreichen internistischen Erkrankungen auf. Im Gegensatz zu Pruritus bei Hauterkrankungen liegen bei Patienten mit internistischen Erkrankungen keine primären Hautveränderungen vor. Allerdings kann intensives Kratzen zu sekundären Hautveränderungen wie Erosionen, Exkoriationen, Krusten, Prurigo nodularis und als Folge auch zu Narbenbildung führen. Die häufigsten internistischen Ursachen für chronischen Pruritus stellen die chronische Niereninsuffizienz, Leber- und Gallengangserkrankungen, hämatoonkologische Erkrankungen sowie Medikamentennebenwirkungen dar. Seltener tritt dieses Symptom bei Patienten mit endokrinen oder metabolischen Störungen, Malassimilationssyndromen, Infektionskrankheiten sowie soliden Tumoren auf. Die Pathogenese des Pruritus bei internistischen Erkrankungen ist noch weitgehend ungeklärt, erste Erkenntnisse liegen für den urämischen und cholestatischen Pruritus vor. Die antipruritische Behandlung ist daher meist symptomatisch und kann eine klinische Herausforderung darstellen. Bei chronischer Niereninsuffizienz ist die Wirksamkeit der Kalziumkanal-Blocker Gabapentin und Pregabalin am besten belegt. In Japan ist der κ‑Opioidrezeptor-Agonist Nalfurafin zugelassen. Eine UVB-Lichttherapie kann ebenfalls Linderung bringen. Bei hepatobiliären Erkrankungen ist neben dem Gallensalzbinder Cholestyramin der Enzyminduktor Rifampicin effektiv. Ebenfalls kommen Bezafibrat, μ‑Opioidrezeptor-Antagonisten und in Japan Nalfurafin zum Einsatz. Für die Behandlung anderer internistischer Erkrankungen liegen dagegen keine randomisierten kontrollierten Studien vor, und die Behandlung ist symptomorientiert und richtet sich auf eine effektive Therapie der Grunderkrankung.
Abstract
Chronic pruritus is a symptom of various internal disorders. In contrast to dermatological diseases, pruritus does not present with primary skin alterations in these patients. However, intense scratching my cause secondary skin changes such as abrasion, excoriation, prurigo nodularis, or in rare cases even scarring. The most common internal causes for chronic pruritus are chronic kidney disease, hepatobiliary, and hematological disorders as well as adverse drug reactions. Pruritus is less commonly seen in patients with endocrine or metabolic diseases, malabsorption syndromes, infectious diseases, and solid tumors. The pathogenesis of pruritus in these disorders remains largely elusive, albeit first insights have been gained for uremic and cholestatic pruritus. Antipruritic treatment is therefore symptomatic in most cases and may represent a clinical challenge. The calcium channel blockers gabapentin and pregabalin have the best proven efficacy in chronic kidney disease associated pruritus. In Japan, nalfurafine, a κ-opioid receptor agonist, has been licensed for this indication. UVB light may also attenuate uremic symptoms. In patients suffering from hepatobiliary disorders the sequestrant cholestyramine and the enzyme inducer rifampicin are effective. Furthermore, bezafibrate, the μ‑opioid receptor antagonists and, in Japan, nalfurafine may be used to ameliorate cholestatic pruritus. So far, no randomized controlled trials have been performed for chronic itch in other internal disorders. Antipruritic treatment is symptom-based with a focus on the effective therapy of the underlying disease.
Abbreviations
- ATX:
-
Autotaxin
- HBV:
-
Hepatitis-B-Virus
- HCV:
-
Hepatitis-C-Virus
- HIV:
-
Humanes Immundefizienzvirus
- H. p.:
-
Helicobacter pylori
- HSV:
-
Herpes-simplex-Virus
- IBAT:
-
Ilealer Gallensalztransporter
- PBC:
-
Primär biliäre Cholangitis
- PSC:
-
Primär sklerosierende Cholangitis
- PV:
-
Polycythaemia vera
- SSC:
-
Sekundär sklerosierende Cholangitis
- UDCA:
-
Ursodeoxycholsäure
- UVB:
-
Ultraviolettes B‑Licht
- VZV:
-
Varicella-zoster-Virus
Literatur
Verwendete Literatur
Afifi Y, Aubin F, Puzenat E et al (2004) Pruritus sine materia: a prospective study of 95 patients. Rev Med Interne 25:490–493
Bergasa NV, Mehlman JK, Jones EA (2000) Pruritus and fatigue in primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol 14:643–655
Berger TG, Shive M, Harper GM (2013) Pruritus in the older patient: a clinical review. JAMA 310:2443–2450
Beuers U (2006) Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 3:318–328
Beuers U, Boberg KM, Chapman RW, Chazouilleres O, Invernizzi P, Jones DE, Lammert F, Pares A, Trauner M (2009) EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. J Hepatol 51:237–267
Beuers U, Kremer AE, Bolier R et al (2014) Pruritus in cholestasis: facts and fiction. Hepatology 60:399–407
Chen YC, Chiu WT, Wu MS (2006) Therapeutic effect of topical gamma-linolenic acid on refractory uremic pruritus. Am J Kidney Dis 48:69–76
Corpechot C, Chazouilleres O, Rousseau A et al (2018) A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med 378:2171–2181
Feng J, Luo J, Yang P et al (2018) Piezo2 channel-Merkel cell signaling modulates the conversion of touch to itch. Science 360:530–533
Geenes V, Williamson C (2009) Intrahepatic cholestasis of pregnancy. World J Gastroenterol 15:2049–2066
Gobbi PG, Attardo-Parrinello G, Lattanzio G et al (1983) Severe pruritus should be a B-symptom in Hodgkin’s disease. Cancer 51:1934–1936
Johannesdottir SA, Farkas DK, Vinding GR et al (2014) Cancer incidence among patients with a hospital diagnosis of pruritus: a nationwide Danish cohort study. Br J Dermatol 171:839–846
Jones EA, Bergasa NV (2000) Evolving concepts of the pathogenesis and treatment of the pruritus of cholestasis. Can J Gastroenterol 14:33–40
Kilic A, Gul U, Soylu S (2007) Skin findings in internal malignant diseases. Int J Dermatol 46:1055–1060
Kimmel M, Alscher DM, Dunst R et al (2006) The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients. Nephrol Dial Transplant 21:749–755
Kirito K, Suzuki K, Miyamura K et al (2018) Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly. Int J Hematol 107:173–184
Kremer AE, Bolier R, van Dijk R et al (2014) Advances in pathogenesis and management of pruritus in cholestasis. Dig Dis 32:637–645
Kremer AE, Martens JJ, Kulik W et al (2010) Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology 139:1008–1018
Kumagai H, Ebata T, Takamori K et al (2010) Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 25:1251–1257
Kuypers DR, Claes K, Evenepoel P et al (2004) A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy. Nephrol Dial Transplant 19:1895–1901
Mesa RA, Niblack J, Wadleigh M et al (2007) The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 109:68–76
Mettang T, Kremer AE (2015) Uremic pruritus. Kidney Int 87:685–691
Pauli-Magnus C, Klumpp S, Alscher DM et al (2000) Short-term efficacy of tacrolimus ointment in severe uremic pruritus. Perit Dial Int 20:802–803
Rayner HC, Larkina M, Wang M et al (2017) International comparisons of prevalence, awareness, and treatment of pruritus in people on hemodialysis. Clin J Am Soc Nephrol 12:2000–2007
Reich A, Stander S, Szepietowski JC (2009) Drug-induced pruritus: a review. Acta Derm Venereol 89:236–244
Reig A, Sese P, Pares A (2018) Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response. Am J Gastroenterol 113:49–55
Strumia R, Varotti E, Manzato E et al (2001) Skin signs in anorexia nervosa. Dermatology 203:314–317
Sukul N, Speyer E, Tu C et al (2019) Pruritus and patient reported outcomes in non-dialysis CKD. Clin J Am Soc Nephrol 14:673–681
Vannucchi AM, Antonioli E, Guglielmelli P et al (2007) Clinical profile of homozygous JAK2 617V〉F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110:840–846
Verstovsek S, Passamonti F, Rambaldi A et al (2014) A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer 120:513–520
Weiss M, Mettang T, Tschulena U et al (2015) Prevalence of chronic itch and associated factors in haemodialysis patients: a representative cross-sectional study. Acta Derm Venereol 95:816–821
Weisshaar E, Weiss M, Mettang T et al (2015) Paraneoplastic itch: an expert position statement from the Special Interest Group (SIG) of the International Forum on the Study of Itch (IFSI). Acta Derm Venereol 95:261–265
Wu HY, Peng YS, Chen HY et al (2016) A comparison of uremic pruritus in patients receiving peritoneal dialysis and hemodialysis. Medicine 95:e2935
Yamaoka H, Sasaki H, Yamasaki H et al (2010) Truncal pruritus of unknown origin may be a symptom of diabetic polyneuropathy. Diabetes Care 33:150–155
Yue J, Jiao S, Xiao Y et al (2015) Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind study. Int Urol Nephrol 47:161–167
Weiterführende Literatur
Pisoni RL, Wikstrom B, Elder SJ et al (2006) Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 21:3495–3505
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
A.E. Kremer und T. Mettang geben an, dass kein Interessenkonflikt besteht.
Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Additional information
Redaktion
H. Haller, Hannover
T. Werfel, Hannover
Der Beitrag ist eine leicht überarbeitete Übernahme aus: Kremer AE, Mettang T (2016) Pruritus bei systemischen Erkrankungen. Hautarzt 67:606. https://doi.org/10.1007/s00105-016-3826-y
Rights and permissions
About this article
Cite this article
Kremer, A.E., Mettang, T. Pruritus bei systemischen Erkrankungen. Internist 60, 814–820 (2019). https://doi.org/10.1007/s00108-019-0637-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00108-019-0637-0